GLPwatch
Papers (12034)
Page 109 of 201, ranked by citation count.
- Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review.
- Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries.
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
- A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada.
- Prescribing Trends in Glucagon-Like Peptide-1 Medications Among Pregnant and Postpartum Persons.
- Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes.
- Liraglutide, a GLP-1 agonist, as a new adjunct treatment in Hailey-Hailey disease: a case report.
- Exendin-4 protects murine pancreatic β-cells from free fatty acid-induced apoptosis through PI-3K signaling.
- Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.
- Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial.
- Liraglutide stimulates the β-catenin signaling cascade in mouse epididymal fat tissue.
- Adherence to and Dropout from Liraglutide 3.0 mg Obesity Treatment in a Real-World Setting.
- Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.
- [Association between SORCS1 rs1416406 and therapeutic effect of exenatide].
- Switching from insulin to liraglutide improved glycemic control and the quality of life scores in a case of type 2 diabetes and active Crohn's disease.
- Anti-obesity Drugs for the Treatment of Binge Eating Disorder: Opportunities and Challenges.
- Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial.
- A Rare Case of Dulaglutide-Associated Angioedema in a Male Patient.
- Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes: The LAMP Randomized Clinical Trial.
- Association of tirzepatide use with risk of osteoporosis compared with other GLP-1 receptor agonists: A retrospective cohort study using the TriNetX database.
- Once-Weekly Semaglutide in Adolescents with Obesity. Reply.
- Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management.
- GPs can prescribe tirzepatide to priority patient groups from June.
- GLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: Database and Systematic Review of Otolaryngologic Adverse Events.
- Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care.
- Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan-L trial.
- High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes.
- Efficacy and safety of once-weekly exenatide after switching from twice-daily exenatide in patients with type 2 diabetes.
- Effect of liraglutide combined with metformin or acarbose on glucose control in type 2 diabetes mellitus and risk factors of gastrointestinal adverse reactions.
- The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials.
- GLP-1 receptor agonists in Alzheimer's and Parkinson's disease: endocrine pathways, clinical evidence, and future directions.
- The effects of exendin-4 treatment on graft failure: an animal study using a novel re-vascularized minimal human islet transplant model.
- Comparative efficacy and safety of semaglutide 2.4 mg and tirzepatide 5-15 mg in obesity with or without type 2 diabetes: A systematic review of Phase 3 clinical trials.
- A Diabetic Patient Complicated With Pancreatic Cancer After Using Liraglutide: A Case Report.
- One Year of Exercise After Weight Loss Increases Postprandial GLP-1 Secretion in Contrast to Usual Activity or GLP-1 Receptor Agonist Treatment.
- Gastroparesis With the Initiation of Liraglutide: A Case Report.
- Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis.
- Mono-PEGylates of exenatide in branched and dimeric structures can improve in vivo stability and hypoglycemic bioactivity.
- A peripherally restricted cannabinoid-1 receptor inverse agonist promotes insulin secretion and protects from cytokine toxicity in human pancreatic islets.
- Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results.
- Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety.
- The GLP-1 Receptor Agonist Liraglutide Decreases Primary Bile Acids and Serotonin in the Colon Independently of Feeding in Mice.
- Preparation of [<sup>177</sup>Lu]Lu-DOTA-Ahx-Lys40-Exendin-4 for radiotherapy of insulinoma: a detailed insight into the radiochemical intricacies.
- The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
- The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials.
- Improved human islet preparations using glucocorticoid and exendin-4.
- Extensive Deep Vein Thrombosis in a Young Man Taking Tirzepatide for Weight Loss.
- Pancreatitis associated with incretin-based therapies.
- Liraglutide for management of adolescent obesity.
- Liraglutide reduces systolic blood pressure in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials.
- Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis.
- Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes.
- Effects of liraglutide addition to multiple diabetes regimens on weight and risk of hypoglycemia for a cohort with type 2 diabetes followed in primary care clinics in Saudi Arabia.
- The Obesity Paradox of Cardiovascular Outcomes in Patients with Diabetes Mellitus.
- Early clinical studies with liraglutide.
- Semaglutide promotes bone marrow-derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.
- Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight.
- Pilot study to test the safety, tolerability and feasibility of dulaglutide during a low-energy diet for weight loss and improved glycaemic control.
- Effect of acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, and estrus phase on cue- and drug-induced fentanyl seeking in female rats.
- New hope for devastating neurodegenerative disease.